Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT07475806 |
| Consolidated Lead Sponsor | Astellas Pharma |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 240 participants (ESTIMATED) |
| Registered Start Date | 2026-03-12 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | Open Hospital Dossier -> |
| Karmanos Cancer Institute | Detroit, MI | Open Hospital Dossier -> |
| NYU Langone Health and Perlmutter Cancer Center | New York, NY | Open Hospital Dossier -> |
| Thomas Jefferson University | Philadelphia, PA | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.